Related Experiment Video

Updated: Aug 30, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

[Treatment of infections associated with Clostridium difficile]

Adam Szczesny1, Gajane Martirosian

  • 1II Zakładu Anestezjologii i Intensywnej Terapii SP CSK Akademii Medycznej w Warszawie.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|October 7, 2003
PubMed

Insights

Antibiotic-associated diarrhea (AAD) and Clostridioides difficile infection (CDI) are increasing, often linked to broad-spectrum antibiotic overuse. Even standard treatments may fail, highlighting the need for new strategies.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Gastroenterology

Background:

  • Antibiotic-associated diarrhea (AAD) and Clostridioides difficile infection (CDI) are increasingly prevalent.
  • Overuse of broad-spectrum antibiotics disrupts intestinal microflora, reducing colonization resistance.
  • C. difficile strains are found in hospital environments, posing a transmission risk.

Purpose of the Study:

  • To review and discuss current treatment methods for C. difficile-associated infections.
  • To highlight the challenges in managing AAD and CDI, including treatment failures.
  • To emphasize the role of risk factors in suspected C. difficile infections.

Main Methods:

  • Review of recent publications on C. difficile-associated infections.
  • Analysis of diagnostic data from Polish studies on AAD and pseudomembranous colitis (PMC).
  • Identification of C. difficile strains in clinical and hospital environmental samples.

Main Results:

  • C. difficile strains confirmed in 52% of suspected AAD/PMC cases in Polish studies.
  • C. difficile isolated from 10.5% of hospital environment samples.
  • AAD/PMC cases reported even after treatment with vancomycin or metronidazole.

Conclusions:

  • Uncontrolled antibiotic use contributes to rising C. difficile infections in Poland.
  • Standard treatments may be insufficient, necessitating exploration of alternative therapeutic approaches.
  • Age, hospitalization duration, surgery, and colonoscopy are key risk factors for CDI.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...